Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2005-03-03
2008-08-19
Saunders, David A (Department: 1644)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
Reexamination Certificate
active
07414121
ABSTRACT:
The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusio proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.
REFERENCES:
patent: 4468457 (1984-08-01), Goldenberg et al.
patent: 4735210 (1988-04-01), Goldenberg
patent: 4737453 (1988-04-01), Primus
patent: 4792521 (1988-12-01), Shochat
patent: 4818709 (1989-04-01), Primus
patent: 4863713 (1989-09-01), Goodwin et al.
patent: 4971792 (1990-11-01), Steplewski et al.
patent: 5078998 (1992-01-01), Bevan et al.
patent: 5101827 (1992-04-01), Goldenberg
patent: 5128119 (1992-07-01), Griffiths
patent: 5183756 (1993-02-01), Schlom
patent: 5225541 (1993-07-01), Hackett et al.
patent: 5274076 (1993-12-01), Barbet et al.
patent: 5328679 (1994-07-01), Hansen et al.
patent: 5469854 (1995-11-01), Unger et al.
patent: 5502037 (1996-03-01), Kondratyev
patent: 5503987 (1996-04-01), Wagner
patent: 5534254 (1996-07-01), Huston
patent: 5591828 (1997-01-01), Bosslet et al.
patent: 5683694 (1997-11-01), Bagshawe et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5697902 (1997-12-01), Goldenberg
patent: 5716595 (1998-02-01), Goldenberg
patent: 5746996 (1998-05-01), Govindan et al.
patent: 5753206 (1998-05-01), McBride et al.
patent: 5772981 (1998-06-01), Govindan et al.
patent: 5776093 (1998-07-01), Goldenberg
patent: 5776094 (1998-07-01), Goldenberg
patent: 5776095 (1998-07-01), Goldenberg
patent: 5837242 (1998-11-01), Holliger et al.
patent: 5837243 (1998-11-01), Deo et al.
patent: 5851527 (1998-12-01), Hansen
patent: 5959083 (1999-09-01), Bosslet et al.
patent: 6010680 (2000-01-01), Govindan et al.
patent: 6077499 (2000-06-01), Griffiths
patent: 6096289 (2000-08-01), Goldenberg
patent: 6121424 (2000-09-01), Whitlow et al.
patent: 6126916 (2000-10-01), McBride
patent: 6187284 (2001-02-01), Griffiths
patent: 6962702 (2005-11-01), Hansen
patent: 7074405 (2006-07-01), Hansen
patent: 7091321 (2006-08-01), Gillies et al.
patent: 2002/0006379 (2002-01-01), Hansen et al.
patent: 0263046 (1988-04-01), None
patent: 0419387 (1991-03-01), None
patent: 0511011 (1992-10-01), None
patent: 0517024 (1992-12-01), None
patent: 0623675 (1994-11-01), None
patent: 921782 (1992-12-01), None
patent: 03173900 (1991-07-01), None
patent: WO 9604313 (1996-02-01), None
patent: WO 97/41898 (1997-11-01), None
patent: WO 9808875 (1998-03-01), None
patent: WO 99/66951 (1999-12-01), None
patent: WO 00/34317 (2000-06-01), None
McGuinness et al. Phage diabody repertoires for selection of large numbers of bispecific antibody fragments, Nature Biotechnology. 14:1149-1154 (1996).
Alt et al. “Novel tetravalent and bispecific lgG-like antibody molecules combining single chain diabodies with the immunogolbulin gamma-1 or CH3 region,” FEBBS Lett 454: 90-94 (1999).
Olafsen et al., “1gm secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic Cells,” lmmunotechnology, 4(2):141-153 (1998).
Kipriyanov et al. “Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics,” J. Mol. Biol., 293(1):41-56 (1999).
Karacay et al. “Studies on a humanized anti-CEA x murine anti-(In- DTPA) bispecific antibody construct for radioimmunotherapy of CEA-positive tumors,” Proceedings of the American Association for Cancer Research Annual Meeting, vol. 40, p. 644, (Mar. 1999).
Karacay et al., “Pretargeting studies with a humanized anti-CEAX murine anti-(In-DTPA) bispecific antibody construct and Tc-99m/Re-188 labeled peptide,” Journal of Nuclear Medicine, vol. 40, No. 5 Suppl., p. 225 (May 1999).
Gautherot et at “Delivery of therapeutic doses of radiojodine using bispecific antibody—targeted bivalent haptens,” Journal of Nuclear Medicine, vol. 39 (11), pp. 1937-1943 (Nov. 1998).
Bodere et al. “Phase I/II total of two-step radioimmunotherapy in medullary thyroid cancer (MTC) using bispecific anti-CEA/anti- DTPA—in antibody and iodine-131-labeled bivalent hapten,” Journal of Nuclear Medicine, vol. 39, No. 5 Suppl, p. 246 (May 1998).
Bardies et at Bispecific antibody and Iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-ceil lung cancer,˜ Journal of Nuclear Medicine, vol. 37, pp. 1853-1859 (Nov. 1996).
Kraeber-Booere et al. Bispecific antibody and bivalent hapten radloimmunotherapy in CEA producing medullary thyroid cancer xenograft, Journal of Nuclear Medicine, vol. 40, (1), pp. 198-204 (Jan. 1999).
Hosono et at. “Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.” Journal of Nuclear Medicine, vol. 39 (9), pp. 1608-1613 (Sep. 1998).
Kranenborg et at “Development and characterization of and-renal cell carcinoma x antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma,” Cancer Research, vol. 55(23 Suppl.), pp. 55643-5867S (Dec. 1, 1995).
Kranenborg et at. Two-step radio-immunotargeting of renal-cell carcinoma xenografts in nude mice with anti-renal-cell-carcinoma X anti-DTPA bispecific monoclonal antibodies, International Journal of Cancer, vol. 75(1), pp. 74-80 (Jan. 5, 1998).
Gautherot Therapy far colon carcinoma xenografts with bispecific antibody—targeted, iodine-131-labeled bivalent hapten, Cancer, vol. 80, No. Suppl. 12, pp. 2618-2623 (Dec. 15, 1997).
Bosslet et al., “Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy,” British Journal of Cancer, vol. 63/5, pp. 681-686 (1991).
Manetti et al., “Intracellular uptake and catabolism of anti-IgM antibodies and bi-specific antibody-targeted hapten by B-lymphoma cells,” Int. J. Cancer, vol. 63(2), pp. 250-256 (1995).
Barbet et al. Radioimmunotherapy of LS174T colon carcinoma in nude mice using an iodine-131-labeled bivalent hapten combined with an anti-CEAX anti-indium- DTPA bispecific antibody, Tumor Biology, vol. 18, No. Suppl. 2, p. 31 (Sep. 1997).
Hawkins et al. “Delivery of Radionuclides to Pretargeted Monoclonal, Antibodies Using Dihydrofolate Reductase and Methotrexagte in an Affinity System,” Cancer Research, vol. 53, pp. 2368-2373, May 1993.
Goodwin et al. “Pre-Targeted Immunoscintigraphy of Murine Tumors with Indium-111-Labeled Bifunctional Haptens,” J. Nucl., Med., vol. 29, pp. 226-234. 1998.
Stickney et al. Bifunctional Antibody: A Binary Radiopharmaceutical Delivery System for Imaging Colorectal Carcinoma, Cancer Research, vol. 51, pp. 6650-6655, Dec. 15, 1991.
Gautherot et al. “Therapy for Colon Carcinoma Xenografts with Bispecific Antobody-Targeted, Iodine-131-Labeled Bivalent Hapten,” Cancer Supplement, vol 80, pp. 2618-2623, 1997.
Barbet et al. Radioimmunodetection of Medullary Thyroid Carcinoma Using Indium-iII Bivalent Hapten and Anti-CEA X Anti-DTPA-Indium, The Journal of Nuclear Medicine, vol. 39, No. 7, Jul. 1998.
Kranenborg et al. “Development and Characterization of Anti-Renal Cell Carcinoma x Antichelate Bispecific Monoclonal Antibodies for Two-Phase Targeting of Renal Cell Carcinoma,” Cancer Research Supplement vol. 55, pp. 5864s-5867s, Dec. 1, 1995.
Cherry et al. Micropet 1: Performance Evaluation of a Very High Resolution Pet Scanner Proceedings of the 44th Annual Meeting Scientific Papers, vol. 38, No. 5, May 1997 Supplement.
Schuhmacher et al., “Multistep Tumor Targeting in Nude ice Using Bispecific Antibodies and a Gallium Chelate Suitable for Immunoscintigrapnhy with Positron Emission Tomography,” Cancer Research, vol. 55, pp. 115-123, Jan. 1, 1995.
Sharkey et al., “Development of a Streptavidin-Anti- Carcinoembryonic Antigen Antibody, Radiolabeled Biotin Pretargeting Method for Radioimmunotherapy of Colorectal Cancer Studies in a Colon Cancer Xenograft Model,”, Bioconjugate Chemical, vol. 8, No. 4, 1997.
Karacay, et al., “Expermental Pretargeting Studies of Cancer with a Humanized anti-CEA x Murine anti-{In-DT
Goldenberg David M.
Hansen Hans J.
Immunomedics Inc.
Nakashima Richard A.
Saunders David A
LandOfFree
Chimeric, human and humanized anti-CSAp monoclonal antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric, human and humanized anti-CSAp monoclonal antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric, human and humanized anti-CSAp monoclonal antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4016596